The novel biotech active delivers clinically demonstrated hyperpigmentation correction and skin brightening at a 0.45% use level, less than half the EU’s maximum concentration for kojic acid in face and hand products.   

SAN DIEGO, Sept. 15, 2026 /PRNewswire/ — Debut, the biotech beauty leader, today announced the launch of DermCeutical PNar™, a biotech active engineered to visibly reduce hyperpigmentation and brighten the skin without the irritation commonly associated with the industry’s most widely used, higher-concentration ingredients such as kojic acid.  

Developed through Debut’s proprietary platform integrating AI, skin genomics and biotechnology, PNar™ was engineered by identifying the underlying biological drivers of hyperpigmentation and designing an entirely new molecule to target them at the source. The ingredient blocks key enzymes, including tyrosinase, to reduce melanin production before dark spots appear.  

Kojic acid has long been the category standard, but recent EU regulatory changes restrict its use to a maximum concentration of 1% in face and hand products, following concerns about its potential endocrine-disrupting properties and dermal absorption. The restriction is part of a broader shift across the beauty industry as regulators increasingly scrutinize higher-concentration active ingredients. 

“For decades, the treatment of hyperpigmentation has forced a trade-off: potent enough to work, or gentle enough to use. PNar™ breaks that compromise, delivering real results without the irritation associated with legacy beauty ingredients,” said Joshua Britton, PhD, Founder and CEO of Debut. “The challenge was to engineer a molecule that could deliver superior performance at a low use level, while driving skin longevity. PNar™ demonstrates what’s possible when you start with biology, identify the precise target, and then design the molecule.”  

PNar™ delivers clinically demonstrated brightening efficacy at a 0.45% use level. In a 12-week clinical study, 97% of users showed improvement in hyperpigmentation and 88% showed improvement in skin brightening. 

Hyperpigmentation is a widespread global skin concern. In a 2025 study of 48,000 adults across 34 countries published in the Journal of Investigative Dermatology, 50% of respondents reported at least one pigmentary disorder, including multiple forms of pigmentation, melasma, and sunspots. PNar™ is designed to work across all skin tones, addressing hyperpigmentation and uneven skin tone while being gentle on the skin.  

“The next generation of skincare won’t come from pushing existing ingredients to higher concentrations. It will come from engineering entirely new molecules for precision targeting,” said Britton.  

PNar™ is now available to brand partners through Debut’s formulation business in the US.

Debut 

Beauty starts with biology 

Debut is building the future of beauty through biology. Using the largest and most accurate proprietary skin genomic database to power its AI discovery engine, Debut creates high-performing and clinically proven formulations that deliver maximum efficacy, and brings them to market at unprecedented speed to fuel the innovation of all beauty brands. Named to the TIME100 Most Influential Companies of 2025, Debut is setting a new standard for beauty innovation with performance at its core.

View original content to download multimedia:https://www.prnewswire.com/news-releases/debut-engineers-new-biotech-ingredient-for-hyperpigmentation-302878244.html

SOURCE Debut